share_log

Vivos Therapeutics | CORRESP: CORRESP

Vivos Therapeutics | CORRESP: CORRESP

Vivos Therapeutics | CORRESP:信函
美股sec公告 ·  04/24 12:56
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.
Vivos Therapeutics, Inc. has formally requested the U.S. Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form S-1, initially filed on April 9, 2024. The company seeks to have the registration become effective at 4:30 p.m. on April 26, 2024. This request was made under Rule 461 of the Securities Act of 1933, as amended. Additionally, Vivos Therapeutics has authorized Lawrence A. Rosenbloom, Esq. of Ellenoff Grossman & Schole LLP to communicate with the SEC staff regarding any potential deferral of the new effective time.
Vivos Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)加快其最初於2024年4月9日提交的S-1表格註冊聲明的生效。該公司希望註冊於2024年4月26日下午4點30分生效。該請求是根據經修訂的1933年《證券法》第461條提出的。此外,Vivos Therapeutics已授權埃倫諾夫·格羅斯曼和斯科爾律師事務所的勞倫斯·羅森布魯姆先生就新生效時間的任何可能延期與美國證券交易委員會工作人員進行溝通。
Vivos Therapeutics, Inc.已正式要求美國證券交易委員會(SEC)加快其最初於2024年4月9日提交的S-1表格註冊聲明的生效。該公司希望註冊於2024年4月26日下午4點30分生效。該請求是根據經修訂的1933年《證券法》第461條提出的。此外,Vivos Therapeutics已授權埃倫諾夫·格羅斯曼和斯科爾律師事務所的勞倫斯·羅森布魯姆先生就新生效時間的任何可能延期與美國證券交易委員會工作人員進行溝通。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息